223 related articles for article (PubMed ID: 33895717)
1. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.
Baral R; Higgins D; Regan K; Pecenka C
BMJ Open; 2021 Apr; 11(4):e046563. PubMed ID: 33895717
[TBL] [Abstract][Full Text] [Related]
2. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
3. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
4. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
[TBL] [Abstract][Full Text] [Related]
6. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
[TBL] [Abstract][Full Text] [Related]
8. Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis.
Laufer RS; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Driscoll AJ; Galvani AP; Keita AM; Neuzil KM; Sow S; Pecenka C; Ortiz JR; Fitzpatrick MC
PLOS Glob Public Health; 2023; 3(5):e0001432. PubMed ID: 37145993
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Getaneh AM; Li X; Mao Z; Johannesen CK; Barbieri E; van Summeren J; Wang X; Tong S; Baraldi E; Phijffer E; Rizzo C; van Wijhe M; Heikkinen T; Bont L; Willem L; Jit M; Beutels P; Bilcke J;
Vaccine; 2023 Feb; 41(9):1623-1631. PubMed ID: 36737318
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
Laufer RS; Driscoll AJ; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Galvani AP; Haidara FC; Kotloff KL; Keita AM; Neuzil KM; Orenstein EW; Orenstein LAV; Pecenka C; Sow S; Tapia MD; Ortiz JR; Fitzpatrick MC
Vaccine; 2021 Aug; 39(35):5037-5045. PubMed ID: 34325934
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
Li X; Hodgson D; Flaig J; Kieffer A; Herring WL; Beyhaghi H; Willem L; Jit M; Bilcke J; Beutels P;
Value Health; 2023 Apr; 26(4):508-518. PubMed ID: 36442831
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
Liu D; Leung K; Jit M; Wu JT
Vaccine; 2021 Sep; 39(39):5490-5498. PubMed ID: 34454783
[TBL] [Abstract][Full Text] [Related]
16. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
[TBL] [Abstract][Full Text] [Related]
17. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
Srikantiah P; Klugman KP
BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
[TBL] [Abstract][Full Text] [Related]
18. A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.
Maculaitis MC; Hauber B; Beusterien KM; Will O; Kopenhafer L; Law AW; Vietri JT; Cappelleri JC; Coulter JR; Pugh S; Shea KM
Hum Vaccin Immunother; 2024 Dec; 20(1):2358566. PubMed ID: 38847198
[TBL] [Abstract][Full Text] [Related]
19. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
Wittenauer R; Pecenka C; Baral R
BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
